ABSTRACT
OBJECTIVE: This open prospective study was performed to investigate the therapeutic efforts and side effects profiles of nemonapride in the schizophrenic patients, and was compared with one of typical anti-psychotics, haloperidol. METHOD: Sixty male or female schizophrenic patients were treated for 12 weeks with nemonapride(n=32) and haloperidol(n=28). The overall clinical therapeutic effects were assessed at baseline, 1st week, 2nd week, 4th week, 8th week and 12th week using the PANSS, the BPRS and the CGI scale. Also, the overall clinical side effects were assessed in the same time period using ESRS, UKU side effect rating scale and global assessment for side effect scale. RESULTS: There were not a significant differences in PANSS score(total, positive, negative and general psychopathology subscale), BPRS(total score), CGI scale score between nemonapride and haloperidol trial groups. And also, there were not a significant differences in the ESRS, the UKU side effect rating scale, the Global assessment far side effect stale score between nemonapride and haloperidol trial groups. 59% of the nemonapride-treated patients(n=32) were categorized as treatment responders, who showed at least a 20% decrease in total PANSS score at baseline state, was compared with 64% of haloperidol-treated patients(n=28). 72% of the nemonapride-treated patients were categorized as treatment responders, who showed at least a 20% decrease in total BPRS score at baseline state, compared with 68% of haloperidol-treated patients. There were not significant differences in these both treatment responder groups. CONCLUSION: There were no significant differences in the therapeutic effects and side effects profiles of nemonapride and haloperidol groups.
Subject(s)
Female , Humans , Male , Haloperidol , Prospective Studies , Psychopathology , SchizophreniaABSTRACT
This study was done to compare the effects of nemonapride on cognitive and psychomotor performance and sedation with those of classical antipsychotics in normal adults. Single doses of three antipsychotics (chlorpromazine 50mg, haloperidol 2mg and nemonapride 3mg) and placebo were given to 8 healthy male volunteers at weekly intervals, in a double-blind Latin square design. All subjects completed a battery of cognitive and psychomotor pelformance tests (Critical Flicker Fusion Threshold : CFFT, Choice Reaction Time : CRT, Compensatory Tracking Test : CTT, Digit-Symbol Substitution Test DSST) and self-estimate for sedation using visual analog rating scales at pre-dose and 2, 4, 6, 8hr post-dose. The results were as follows : 1) Chlorpromazine 50mg significantly impaired CFFT, CRT, CTT and DSST compared to placebo and showed the most potent sedative effect among the test drugs. These effects occurred in almost all ranges of time points with peak effEct at 4hr post-dose. 2) Haloperidol 2 mg did not impair any cognitive or psychomotor performances. There was no sedative effect as well. 3) Nemo-napride 3 mg selectively impaired CFFT (at 2 and 6hr post-dose), total reaction time (at 4hr post-dose) of CRT and DSST (at 4 and 6hr post-dose). Sedative effect occurred more significantly than placebo at 4 and 6 hr post-dose. These results indicate that nemonapride 3mg seems to have the intermediate profiles between chlorpromazine 50mg and haloperidol 2mg in terms of cognitive and psychomotor effects as well as sedative effect. In addition, inspection of the results suggest that the cognitive and psychomotor effects could be secondary to sedative effect.